Today 111, Inc. (YI) Stock Crashes

The stock of 111, Inc. (NASDAQ:YI) is a huge mover today! The stock decreased 14.76% or $0.84 during the last trading session, reaching $4.85. About 615,568 shares traded or 669.22% up from the average. 111, Inc. (NASDAQ:YI) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.
The move comes after 8 months negative chart setup for the $489.89M company. It was reported on Sep, 13 by Barchart.com. We have $4.66 PT which if reached, will make NASDAQ:YI worth $19.60 million less.

More notable recent 111, Inc. (NASDAQ:YI) news were published by: Seekingalpha.com which released: “U.S. IPO Week Ahead: No IPOs, But Plenty Of Potential Launches – Seeking Alpha” on March 10, 2019, also Benzinga.com with their article: “Stocks That Managed to Breach 52-Week Lows Friday – Benzinga” published on July 26, 2019, Nasdaq.com published: “Hong Kong’s Cathay Pacific warns against protest outside its premises – Nasdaq” on August 27, 2019. More interesting news about 111, Inc. (NASDAQ:YI) were released by: Streetinsider.com and their article: “111, Inc. (YI) Reports Q2 Loss of $0.15, Revenues Miss – StreetInsider.com” published on August 15, 2019 as well as Nasdaq.com‘s news article titled: “Chinese online pharmacy 111 sets terms for $140 million US IPO – Nasdaq” with publication date: August 29, 2018.

111, Inc., through its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. The company has market cap of $489.89 million. The firm sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. It currently has negative earnings. The Company’s product portfolio comprises drugs, nutritional supplements, contact lenses, medical supplies and devices, and personal care and baby products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.